ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Approves Novartis's Afinitor For Kidney Tumors

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Thursday granted wider approval to Novartis AG's (NVS, NOVN.VX) Afinitor to treat non-cancerous kidney tumors that don't require immediate surgery. Afinitor was first approved in the U.S. in 2009 to treat kidney cancer after treatment with other drugs fail. Afinitor was approved Thursday to treat kidney tumors that are caused by a rare genetic disese called tuberous sclerosis complex, or TSC. According to FDA, the disease causes the growth of various non-cancerous tumors in the brain, kidney and other vital organs. It affects about 40,000 patients in the U.S., the majority of which develop kidney problems. TSC generally causes multiple tumors in both kidneys, which eventually cause kidney failure and bleeding. Afinitor, a pill taken once daily, blocks the uncontrolled activity of a protein called mTOR, which plays a role in the development and growth of certain tumors. Afinitor is also approved to treat certain kinds of brain and pancreatic tumors. The FDA said the approval of Afinitor for use in treating kidney tumors from TSC was based on a study involving 118 patients. About two-thirds of the patients received Afinitor and one-third were received a placebo, or fake pill. Patients receiving the placebo later had the option to receive Afinitor if their kidney tumors grew. FDA said the study showed about 42% of patients treated with Afinitor experienced "substantial" shrinkage of their tumors which lasted more than five months on average. None of the patients on the placebo had tumor shrinkage. Novartis is being required to keep following patients in the study for at least four years. FDA said the most common side effects with Afinitor were sore mouth, nausea or vomiting, skin problems, cough, headache, diarrhea, abdominal pain, joint pains, swelling of legs or arms, and upper respiratory infections. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
02/09/201613:00:00Novartis Reaches Entresto Pay-for-Performance Deals With Cigna...
02/09/201612:57:00Novartis Reaches Entresto Pay-for-Performance Deals With Cigna...
02/03/201611:04:00Investors' Fears Eased as Glaxo Posts Solid Results -- Update
02/03/201608:30:00GlaxoSmithKline Posts $510 Million Net Loss
02/03/201608:23:00GlaxoSmithKline Posts GBP354 Million Net Loss in 4Q
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/27/201616:30:00Radius Health Announces Clinical Collaboration With a Leading...
01/27/201609:57:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201605:10:00Global Stocks Edge Lower Ahead of U.S. Interest Rate Decision
01/27/201604:44:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201603:01:00Novartis Net Profit Falls 57% --Update
01/27/201602:50:00Novartis Net Profit Falls 57%
01/27/201602:02:00Novartis 4Q Net Profit Falls 57% as Eye-Care Unit Drags on Results
01/22/201611:53:00CEOs Sanguine on M&A Prospects in Spite of Markets Dive --Update
01/22/201609:06:00Novartis AG 4Q 2015 -- Forecast
01/20/201619:29:00Drug and Diagnostic Companies Issue Joint Declaration on Antibiotics
01/11/201610:10:00Juno Agrees to Acquire AbVitro
12/17/201519:49:00Ligand Pharma to Buy Genetic Engineering Company OMT -- 2nd Update
12/17/201505:10:00Global Stocks Rally After Fed Decision
12/07/201515:53:00U.S. Stocks Fall as Oil Keeps Sliding

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad